Immunotherapy of melanoma

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue SUPPL. 1, 2010, Pages

  Hersey, Peter ^a  

^a Newcastle Melanoma Unit   (Australia)

Author keywords

Cytotoxic T lymphocyte antigen 4; Immunotherapy; Melanoma; Treatment; Vaccine

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; MELACINE; MELANOMA ANTIGEN; MELANOMA VACCINE; TICILIMUMAB;

ANTIGEN EXPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COLITIS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG ERUPTION; GENE TARGETING; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MELANOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 77950787458     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01269.x     Document Type: Review

References (60)

1. Markovic SN, Erickson LA, Rao RD. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007, 82:490-513.
2. Markovic SN, Erickson LA, Rao RD. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82:364-80.
3. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008, 14:4385-91.
4. Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci (Lond) 2006, 111:93-106.
5. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003, 196:85-108.
6. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999, 11:286-93.
7. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990, 11:211-16.
8. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-18.
9. Bergman ML, Cilio CM, Penha-Goncalves C. CTLA-4-/- mice display T cell-apoptosis resistance resembling that ascribed to autoimmune-prone non-obese diabetic (NOD) mice. J Autoimmun 2001, 16:105-13.
10. Danson S, Lorigan P. Melanoma vaccines - they should work. Ann Oncol 2006, 17:539-41.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-52.
12. Lizee G, Basha G, Jefferies WA. Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation. Trends Immunol 2005, 26:141-9.
13. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003, 21:873-86.
14. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004, 5:7-10.
15. Nair SK, Morse M, Boczkowski D. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002, 235:540-9.
16. Chang AE, Redman BG, Whitfield JR. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002, 8:1021-32.
17. Rouas R, Uch R, Cleuter Y. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther 2002, 9:715-24.
18. Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003, 134:378-84.
19. Tanaka H, Shimizu K, Hayashi T. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002, 220:1-12.
20. Lizee G, Cantu MA, Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res 2007, 13:5250-5.
21. Hersey P, Coates AS, McCarthy WH. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002, 20:4181-90.
22. Sosman JA, Unger JM, Liu PY. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002, 20:2067-75.
23. Finn OJ. Cancer immunology. N Engl J Med 2008, 358:2704-15.
24. Ribas A, Butterfield LH, Glaspy JA. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003, 21:2415-32.
25. Somasundaram R, Swoboda R, Caputo L. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006, 66:3287-93.
26. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007, 25(2):B89-96. Suppl
27. Engell-Noerregaard L, Hansen TH, Andersen MH. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009, 58:1-14.
28. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001, 61:7530-5.
29. Machiels JP, Reilly RT, Emens LA. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001, 61:3689-97.
30. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005, 65:8059-64.
31. Nigam A, Yacavone RF, Zahurak ML. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 1998, 12:161-70.
32. Hersey P, Zhang XD. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol Immunother 2009, 58:1749-59.
33. Hersey P, Bastholt L, Chiarion-Sileni V. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009, 20(6):vi35-40. Suppl
34. Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther 2005, 7:588-97.
35. Tchekmedyian S, Glasby J, Korman A. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol 2002, 21:56.
36. Hodi FS, Mihm MC, Soiffer RJ. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100:4712-17.
37. Fischkoff SA, Hersh E, Weber J. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 2005, 23:Abstract 7525.
38. Attia P, Phan GQ, Maker AV. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-53.
39. Maker AV, Phan GQ, Attia P. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-16.
40. Maker AV, Yang JC, Sherry RM. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006, 29:455-63.
41. Ribas A, Camacho LH, Lopez-Berestein G. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23:8968-77.
42. Ribas A, Antonia S, Sosman J. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol 2007, 25:Abstract 3000.
43. Ribas A, Hanson DC, Noe DA. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007, 12:873-83.
44. Margolin K. Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. Community Oncol 2008, 5:367-74.
45. http://www.clinicaltrials.gov, ClinicalTrials.gov [homepage on the Internet, National Library of Medicine, US_National_Institutes_of_Health, cited 8 Sep 2009]. Available from:
46. Weber JS, Hersh EM, Yellin M. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J Clin Oncol 2007, 25:Abstract 8523.
47. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-72.
48. Yang JC, Beck KE, Blansfield JA. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol 2005, 23:Abstract 2501.
49. Sanderson K, Scotland R, Lee P. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005, 23:741-50.
50. Beck KE, Blansfield JA, Tran KQ. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-9.
51. Robinson MR, Chan CC, Yang JC. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004, 27:478-9.
52. Blansfield JA, Beck KE, Tran K. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005, 28:593-8.
53. Oble DA, Loewe R, Yu P, Mimh MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
54. Downey SG, Klapper JA, Smith FO. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007, 13:6681-8.
55. Korn EL, Liu PY, Lee SJ. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-34.
56. O'Day S, Weber J, Lebbe C. Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009, 27:Abstract 9033.
57. Berman DM, Wolchok J, Weber J. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009, 27:Abstract 3020.
58. Hodi FS, Hoos A, Ibrahim R. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008, 26:Abstract 3008.
59. Ribas A, Comin-Anduix B, Chmielowski B. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009, 15:6267-76.
60. Flaherty K, Puzanov I, Sosman J. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27:Abstract 9000.